Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot Study of the Pharmacokinetics and Safety of Rifabutin 150 mg Once Daily Versus Rifabutin 300 mg Thrice Weekly With Lopinavir/Ritonavir Based HAART in HIV/TB Co-infected Patients

NCT02415985 is registered in ClinicalTrials.gov with The HIV Netherlands Australia Thailand Research Collaboration as lead sponsor.

NCT NCT02415985
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02415985 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot Study of the Pharmacokinetics and Safety of Rifabutin 150 mg Once Daily Versus Rifabutin 300 mg Thrice Weekly With Lopinavir/Ritonavir Based HAART in HIV/TB Co-infected Patients
Lead sponsor
The HIV Netherlands Australia Thailand Research Collaboration
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2015
Completion date
December 31, 2019
Enrollment
40 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

hiv, tuberculosis